The FDA is reviewing Pfizer's new vaccine to treat RSV, a common respiratory illness that can be particularly dangerous for infants and older adults. The fast-tracked development of RSV vaccines follows a particularly rough respiratory season.
The Vaccines and Related Biological Products Advisory Committee, the same group that reviews COVID-19 vaccines, will consider data for Pfizer's RSV vaccine, which is administered to pregnant women to protect infants, next Tuesday, followed by GSK's shot, which is designed for use in adults 60 years and older, on Wednesday. If the panel votes in favor of recommending the vaccines, it could pave the way for full FDA approval later this year.
Pfizer said Tuesday that the FDA is reviewing its maternal RSV vaccine on an expedited basis, with the agency expected to make a decision on whether to greenlight the shot in August. The vaccine was 82% effective at preventing severe disease from RSV in infants during the first 90 days of life when given to pregnant mothers in the late second or third trimester, according to a late-stage trial.
"If approved, RSVpreF would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season,” said Annaliesa Anderson, Pfizer's senior vice president and chief scientific officer on vaccine research and development.The FDA has also granted priority review for GSK's RSV vaccine candidate and is set to take action by May.
The fast-tracked development of RSV vaccine candidates follows a particularly rough respiratory season. Children's hospitals reported an early rise in respiratory diseases, including RSV, among young children last fall, overwhelming their emergency rooms and filling pediatric beds.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer RSV Vaccine That Protects Infants Could Receive FDA Approval This SummerThe single-dose RSV vaccine developed by Pfizer is administered to expectant mothers in the late second-to-third trimester of their pregnancy.
Read more »
FDA agrees to review Pfizer's RSV vaccine for pregnant individualsThe Food and Drug Administration has accepted an application from Pfizer to review its RSV vaccine for pregnant individuals.
Read more »
1st RSV vaccine could be approved by August, pending FDA reviewThe FDA will decide whether or not to approve an RSV vaccine designed to protect newborns by August 2023.
Read more »
1st RSV vaccine could be approved by August, pending FDA reviewPfizer's vaccine would be the first RSV vaccine given to pregnant people to protect infants. The company said that there were 'no safety concerns' for vaccinated pregnant participants and their newborns during the trial.
Read more »
1st RSV vaccine could be approved by August, pending FDA reviewPfizer's vaccine would be the first RSV vaccine given to pregnant people to protect infants. The company said that there were 'no safety concerns' for vaccinated pregnant participants and their newborns during the trial.
Read more »
1st RSV vaccine could be approved this summerAfter decades of research, a first-of-its kind vaccine designed to protect newborns against RSV, or respiratory syncytial virus, could be approved by August.
Read more »